Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Onxeo

Onxeo?uq=UG6efJS6
1997 FOUNDED
PUBLIC STATUS
31-40 EMPLOYEES
ONXEO STOCK SYMBOL
2 INVESTMENTS
$1.13 SHARE PRICE (As of Wednesday Closing)
Description

Developer of medical drugs designed for the treatment of cancer. The company's medical drugs are discovered and developed for the treatment of cancer and supportive care, enabling immune compromised cancer patients to be treated for complications caused by chemotherapy and radiotherapy.

Website
Formerly Known As
Topotarget, BioAlliance Pharma
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
PAR
Primary Office
  • 49 Boulevard du General
  • Martial Valin
  • 75015 Paris
  • France

+33 01 00 00 00 00
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Onxeo’s full profile, request a free trial.

Onxeo Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$1.13 - $2.75 $58.3M $1.15 -$1.32 105K 50.6M

Onxeo Financials Summary

In Thousands,
USD
TTM
30-Jun-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
FY 2015
31-Dec-2015
Enterprise Value 46,684 33,704 87,796 119,959
Revenue 9,827 10,719 4,894 3,863
EBITDA (20,143) (29,459) (23,899) (22,360)
Net Income (67,122) (66,618) (25,077) (21,531)
Total Assets 67,410 93,664 131,568 141,293
Total Debt 117 156 111 75
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Onxeo Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Onxeo‘s full profile, request access.

Request full access to PitchBook

Onxeo Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000 000000000000 25-Mar-2016 000000000000000000 000 Drug Discovery 000000 0000000 00.0
Topotarget 05-Aug-2014 Merger/Acquisition 00000 Drug Discovery
To view this company’s complete investment and acquisition history, request access »

Onxeo Subsidiaries (1)

Company Name Industry Location Founded
0000000000 Drug Discovery Copenhagen, Denmark 0000
To view this company’s complete subsidiary history, request access »

Onxeo Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Onxeo‘s full profile, request access.

Request full access to PitchBook

Onxeo Executive Team (7)

Name Title Board
Seat
Contact
Info
Judith Greciet Ph.D Chief Executive Officer and Board Member
Nicolas Fellmann Chief Financial Officer & Secretary to the Board of Directors
Françoise Bono Chief Scientific Officer
Michel Forest Chief Pharmacist and Quality Assurance Director
Olivier De Beaumont Chief Medical Officer

2 Former Executives

You’re viewing 5 of 7 executives. Get the full list »

Onxeo Board Members (15)

Name Representing Role Since Contact
Info
00000 000000 00.0 Self Member, Supervisory Board 000 0000
0000è00 00000 00000000 Self Independent Director 000 0000
00000 0000000 00.0 Self Independent Director 000 0000
0000-00000 00000000 Self Chairman, Supervisory Board 000 0000
0000-000000 0000000 00 Self Board Member 000 0000

4 Former Board Members

You’re viewing 5 of 15 board members. Get the full list »